背景:由于稀有和各种组织学类型,复发性或转移性唾液腺癌(SGC)的标准化疗方案尚未建立.分子靶向治疗是一种基于靶分子表达的新型癌症治疗方法。然而,很少有分子靶向治疗类型对SGC患者显示出满意的疗效.我们的研究描述了表皮生长因子受体(EGFR)靶向紫杉醇治疗SGC患者的有希望的结果。
方法:回顾性分析2017年12月至2022年12月在我院接受每周一次西妥昔单抗联合紫杉醇(Cmab-PTX)治疗的复发性SGC患者的病历。
结果:7例SGC患者接受Cmab-PTX治疗。中位年龄为76岁。所有患者均为高级别组织学类型,所有检查患者的EGFR表达均为阳性。Cmab-PTX的施用时间中位数为20个月(范围为2-36个月)。总体回答是三个完整的回答,两个有部分反应,一名病情稳定(24周),一个患有进行性疾病。客观反应和疾病控制率分别为71.4%和85.7%,分别。无进展生存期为2至36个月(中位数为12个月),而总生存期为4~111个月(中位36个月).一名患者出现4级不良事件(中性粒细胞减少症),这是保守可控的。
结论:尽管具有高级组织学类型的SGC的治疗敏感性通常较差,Cmab-PTX可能是复发性SGC的有希望的治疗方案。由于稀有和不同的组织学类型,复发性或转移性唾液腺癌(SGC)的标准化疗方案尚未建立.分子靶向治疗是一种基于靶分子表达的新型癌症治疗方法。然而,很少有分子靶向治疗类型在SGC患者中显示出令人满意的疗效.我们的研究描述了西妥昔单抗(Cmab)的有希望的结果,表皮生长因子受体(EGFR)靶向紫杉醇(PTX)治疗SGC患者。7例SGC患者接受Cmab-PTX治疗。中位年龄为76岁。所有患者均为高级别组织学类型,所有检查患者的EGFR表达均为阳性。Cmab-PTX的中位给药时间为20个月。总体回答是三个完整的回答,两个有部分反应,一名病情稳定(24周),一个患有进行性疾病。客观有效率为71.4%。无进展生存期为2至36个月(中位数为12个月),而总生存期为4~111个月(中位36个月).一名患者出现4级不良事件(中性粒细胞减少症),这是保守可控的。我们的研究表明,对于高级别SGC患者,Cmab-PTX的客观缓解率较好。尽管具有高级组织学类型的SGC的治疗敏感性通常较差,Cmab-PTX可能是复发性SGC的有希望的治疗方案。
Due to the rarity and various histological types, a standard chemotherapy regimen for recurrent or metastatic salivary gland carcinoma (SGC) has not been established. Molecular-targeted therapy is a novel cancer therapy based on the expression of target molecules. However, few molecular-targeted therapy types have shown satisfactory efficacy for patients with SGC. Our
study described promising results of epidermal growth factor receptor (EGFR)-targeting therapy with paclitaxel in patients with SGC.
The medical records of patients with recurrent SGC treated with weekly cetuximab combined with paclitaxel (Cmab-PTX) between December 2017 and December 2022 at our institutions were retrospectively analyzed.
Seven patients with SGC received Cmab-PTX therapy. The median age was 76 years. All patients were high-grade histological types, and EGFR expression was positive in all examined patients. Cmab-PTX was administered for a median period of 20 months (range of 2-36 months). The overall responses were three with complete response, two with partial response, one with stable disease (>24 weeks), and one with progressive disease. The objective response and disease control rates were 71.4% and 85.7%, respectively. Progression-free survival ranged between 2 and 36 months (median 12 months), whereas overall survival ranged between 4 and 111 months (median 36 months). One patient experienced a grade 4 adverse event (neutropenia), which was conservatively manageable.
Although the treatment sensitivity of SGC with high-grade histological types is usually poor, Cmab-PTX could be a promising treatment regimen for recurrent SGC. Due to the rarity and various histological types, a standard chemotherapy regimen for recurrent or metastatic salivary gland carcinoma (SGC) has not been established. Molecular-targeted therapy is a novel cancer therapy based on the expression of target molecules. However, few molecular-targeted therapy types have shown satisfactory efficacy in patients with SGC. Our
study described promising results of cetuximab (Cmab), epidermal growth factor receptor (EGFR)-targeting therapy with paclitaxel (PTX) in patients with SGC. Seven patients with SGC received Cmab-PTX therapy. The median age was 76 years. All patients were high-grade histological types, and EGFR expression was positive in all examined patients. Cmab-PTX was administered for a median period of 20 months. The overall responses were three with complete response, two with partial response, one with stable disease (>24 weeks), and one with progressive disease. The objective response rate was 71.4%. Progression-free survival ranged between 2 and 36 months (median 12 months), whereas overall survival ranged between 4 and 111 months (median 36 months). One patient experienced a grade 4 adverse event (neutropenia), which was conservatively manageable. Our
study revealed a preferable objective response rate of Cmab-PTX for patients with high-grade SGC. Although the treatment sensitivity of SGC with high-grade histological types is usually poor, Cmab-PTX could be a promising treatment regimen for recurrent SGC.